Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.

Cilli A., Uzer F., Sevinç C., Coşkun F., Ursavaş A., Öner Ş., ...Daha Fazla

Pulmonary pharmacology & therapeutics, cilt.71, ss.102099, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.pupt.2021.102099
  • Dergi Adı: Pulmonary pharmacology & therapeutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.102099
  • Anahtar Kelimeler: IPF, Nintedanib, Pirfenidone, Switch, ACUTE EXACERBATION, PIRFENIDONE, NINTEDANIB, SAFETY
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: The antifibrotic drugs nintedanib and pirfenidone reduce disease progression in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching first-line antifibrotic drug may required in IPF due to disease progression or intolerable adverse effects. The aim of this study was to assess the safety and efficacy of second-line antifibrotic treatment in patients with IPF.